S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

$1.54
-0.02 (-1.28%)
(As of 04/5/2024)
Today's Range
$1.54
$1.57
50-Day Range
$1.43
$1.92
52-Week Range
$0.60
$4.69
Volume
2.39 million shs
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.68

NGM Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
139.2% Upside
$3.68 Price Target
Short Interest
Healthy
4.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.93) to ($0.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.05 out of 5 stars

Medical Sector

166th out of 913 stocks

Biotechnology Industry

8th out of 65 stocks

NGM stock logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Stock Price History

NGM Stock News Headlines

NGM Biopharmaceuticals (NASDAQ:NGM) Trading Down 1.3%
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
NGM Bio Announces Closing of Tender Offer
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
NGM Bio To Be Acquired By Affiliates Of The Column Group, LP
NGM to go private through deal with investment firm
NGM Biopharmaceuticals, Inc. (NGM)
See More Headlines
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/17/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
Fax
N/A
Employees
138
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$3.68
High Stock Price Target
$6.00
Low Stock Price Target
$1.55
Potential Upside/Downside
+139.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-142,380,000.00
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%

Debt

Sales & Book Value

Annual Sales
$4.42 million
Book Value
$1.80 per share

Miscellaneous

Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. William J. Rieflin J.D. (Age 64)
    Executive Chairman of the Board of Directors
    Comp: $1.1M
  • Dr. David J. Woodhouse Ph.D. (Age 53)
    CEO & Director
    Comp: $860.75k
  • Ms. Valerie L. Pierce J.D. (Age 61)
    Senior VP, General Counsel, Secretary & Chief Compliance Officer
    Comp: $580.75k
  • Dr. Hsiao Dee Lieu F.A.C.C. (Age 54)
    M.D., Chief Medical Officer & Executive VP
    Comp: $625.75k
  • Jean Frederic Viret Ph.D.
    Chief Financial Officer
  • Ms. Irene Perlich
    VP, Corporate Controller & Principal Accounting Officer
  • Mr. Daniel Kaplan Ph.D.
    Chief Scientific Officer
  • Mahi Saraf
    Director of People & Culture
  • Diana Peng Bockus
    Head of Business Development
  • Arthur Hsu Ph.D.
    Senior Director & Head of Biology

NGM Stock Analysis - Frequently Asked Questions

Should I buy or sell NGM Biopharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NGM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGM, but not buy additional shares or sell existing shares.
View NGM analyst ratings
or view top-rated stocks.

What is NGM Biopharmaceuticals' stock price target for 2024?

4 analysts have issued 1-year price targets for NGM Biopharmaceuticals' shares. Their NGM share price targets range from $1.55 to $6.00. On average, they predict the company's stock price to reach $3.68 in the next twelve months. This suggests a possible upside of 139.2% from the stock's current price.
View analysts price targets for NGM
or view top-rated stocks among Wall Street analysts.

How have NGM shares performed in 2024?

NGM Biopharmaceuticals' stock was trading at $0.8590 at the start of the year. Since then, NGM shares have increased by 79.3% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

Are investors shorting NGM Biopharmaceuticals?

NGM Biopharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,390,000 shares, an increase of 42.3% from the March 15th total of 1,680,000 shares. Based on an average trading volume of 1,070,000 shares, the short-interest ratio is presently 2.2 days. Currently, 4.5% of the shares of the company are short sold.
View NGM Biopharmaceuticals' Short Interest
.

When is NGM Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NGM earnings forecast
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its earnings results on Monday, March, 11th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.04. The firm earned $0.17 million during the quarter, compared to analysts' expectations of $2 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did NGM Biopharmaceuticals IPO?

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NGM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners